Bone Biologics Corporation (BBLG)

BBLG.......................................................................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.

To My Fellow Stockholders:

I am pleased to provide a progress report on Bone Biologics’ development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM).

NELL-1 has several unique properties that suggest it will be ideal for treating spinal fusion, trauma, osteoporosis and other bone-related indications, and may be especially useful among so-called “hard healers.” This potential lies in its ability to provide rapid, specific and guided control over bone regeneration. We are optimistic that NB1 may provide an important alternative to a vexing clinical problem by improving the safety profile of an osteopromotive orthobiologic.

First-in-Human Study

We commenced our pilot clinical study with NB1 in Australia last year. This multicenter, prospective, randomized study is evaluating the safety and preliminary effectiveness of NB1 bone graft in patients with degenerative disc disease who are undergoing transforaminal lumbar interbody fusion.

The study is assessing two concentrations of NB1 relative to autograft control in up to 30 subjects. The study’s primary clinical endpoints include fusion success at 12 and 24 months after surgery, and change from the baseline Oswestry Disability Index, which is the gold standard tool to measure a patient’s functional disability. While the clinical trial enrollment has been slower than anticipated, we do expect to complete enrollment by end of the year.

Product Improvements

Stability studies conducted by third parties recently achieved an 18-month shelf life for our protein, representing an improvement from the prior shelf life of 12 months. We also demonstrated improvement in the formulation of our protein that should enable compatibility with the new, scaled semi-automated fill/finish process that will be required for our upcoming pivotal study.

In June, we filed a U.S. patent application directed to the proprietary compositions of rhNELL-1 polypeptide and its uses for treating bone conditions. The patent application, if approved, will support our strategic plan to advance our clinical development program.

One-Year Outlook

We expect to achieve a number of value-creating events in the coming year under our cost-efficient business model, including the following:

Adding additional hospital sites in Australia and completing enrollment in our pilot study by year-end.
Expanding our shelf life to 24 months from 18-months in preparation for increasing manufacturing scale for a pivotal study.
Developing a more robust potency assay to better measure NB1’s biological activity.
Providing an interim update on the trial once all the patients have reached six-month follow up.
On June 30th, we completed a public offering raising gross proceeds of $5 million. We expect our current cash position to fund planned operations into the second quarter of 2026.

The Opportunity for NB1

The scientific basis for developing NB1 is the potential for increased safety and better fusion rates. Spine fusion is a common surgical procedure in the treatment of numerous spinal diagnoses including degenerative disc disease, spinal stenosis, spondylolisthesis and other spinal deformities. A bony fusion is essential for restoring segmental stability, preventing or correcting deformity and improving long-term outcomes. Lumbar intervertebral fusion is achieved by creating an environment that’s conducive to the formation of a continuous osseous bridge across the involved spinal segments.

We remain optimistic that spinal fusion patients will benefit from our solution for hard-to-heal bones, and we are very excited about the potential to help these patients as we advance NB1 along the clinical and regulatory pathway. We believe our effort will be well-rewarded not only by patients, but also by caregivers and Bone Biologics’ stockholders.

I extend thanks to all of our constituents for their ongoing support.

Sincerely,

Jeffrey Frelick
President & Chief Executive Officer
September 4, 2025

About Bone Biologics

Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while ad

The okey-doke!!! File patent - drop SPA!

$BBLG: Yup......... that sucks.......

On that note........... added 3k here at $4.80 now........... $4.50 stop

Lets do it again


GO $BBLG

$BBLG amen to pre market , but what a dump fest with their $5 million dilution dump on investors.
Terrible!!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176370614

OPEN S1 DILUTION !! $BBLG

https://dilutiontracker.com/app/s1
$95 million worth.
Don’t get caught holding the bag..

https://www.sec.gov/Archives/edgar/data/1419554/000164117225016289/forms-1.htm

Bone Biologics Files Patent Application for Bone Regeneration Technology
BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein.

The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.

“This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients,” said Jeffrey Frelick, Chief Executive Officer of Bone Biologics.

The patent application, if approved, will strengthen Bone Biologics’ intellectual property portfolio and support the Company’s strategic plan to advance the clinical development program.

About Bone Biologics Corp.

$BBLG: BOOoooooommmmmmmmmmm............. ROCKETSHIP $11

Just like that from $4 yesterday


AMAAZINNNNGGGGGGGGGGGGGG Friday PLAY here in PreMarket



GO $BBLG

BBLG, new 52 week low

BBLG setting uP a daily Bullish engulfing candle…

BBLG...$1.10...🥳...Accumulating...

BBLG under $2

bblg.............................https://stockcharts.com/h-sc/ui?s=bblg&p=W&b=5&g=0&id=p86431144783

BBLG in Good Shape as Testing Continues
.966

https://finance.yahoo.com/news/bblg-good-shape-testing-continues-110300226.html

whatcha think... maybe the next runner
$BBLG - finviz shows this as a similarly tiny low float play. When vol comes in here the shorts get squeezed as we can see from 2 weeks ago when it spiked to $1.68 and then was walked right back down on low vol. $1.25-30 squeeze spot for volume imo pic.twitter.com/ckg5lkJgkB— buysellshort.net (@buysellshort) December 6, 2024

ice berg order @ 1.07 finally broke

some chatter starting after all these low float parabolic runners

https://x.com/Alertzzzz/status/1869824980101542174

Added

BBLG..................................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

Have a Great Weekend Y'all...🥳

Yes!
BBLG...$2.20s clearing here...🥳...Looking for Upper Bollie Break...
$BBLG

BBLG...$2.20s clearing here...🥳...Looking for Upper Bollie Break...

georgie18

Member Level
Re: georgie18 post# 660033

Friday, October 18, 2024 9:37:06 AM

Post#
661663
of 661723
BBLG...$2.09s clearing here...Open Gap in the $1.80 range...🥳

georgie18

Member Level
Re: georgie18 post# 138

Wednesday, October 02, 2024 11:59:39 AM

Post#
139
of 150
BBLG...$1.74...on the dip opportunity...🥳

georgie18

Member Level
Re: georgie18 post# 659336

Friday, September 27, 2024 10:15:04 AM

Post#
659570
of 660031
BBLG...$2.60...🥳

georgie18

Member Level
Re: georgie18 post# 136

Wednesday, September 25, 2024 3:57:43 PM

Post#
137
of 137
BBLG...$2.38s clearing off the $2.02 dip...🥳

georgie18

Member Level
Re: georgie18 post# 659229

Wednesday, September 25, 2024 12:01:49 PM

Post#
659269
of 659335
BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

BBLG...$2.09s clearing here...Open Gap in the $1.80 range...🥳

georgie18

Member Level
Re: georgie18 post# 138

Wednesday, October 02, 2024 11:59:39 AM

Post#
139
of 150
BBLG...$1.74...on the dip opportunity...🥳

georgie18

Member Level
Re: georgie18 post# 659336

Friday, September 27, 2024 10:15:04 AM

Post#
659570
of 660031
BBLG...$2.60...🥳

georgie18

Member Level
Re: georgie18 post# 136

Wednesday, September 25, 2024 3:57:43 PM

Post#
137
of 137
BBLG...$2.38s clearing off the $2.02 dip...🥳

georgie18

Member Level
Re: georgie18 post# 659229

Wednesday, September 25, 2024 12:01:49 PM

Post#
659269
of 659335
BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

Yup...watching the $2.00s start to hit here...🥳

2.08 on ask now kept a few for final squeeze

Nice trade...🥳

)1.67 last entry flipping out a little at 1.90- 2 holding some for the small float squeeze

BBLG $1.99

Looks good added some still low floater

$BBLG Apparently the analysis price target is $16.75, we will see.

$2 resistance extreme low floater ..The new warrants will be immediately exercisable at an exercise price of $2.00 per share. New warrants to purchase 781,251 shares of common stock will have a term of five years from the issuance date, and new warrants to purchase 781,251 shares of common stock will have a term of eighteen months from the issuance date.

The offering is expected to close on or about August 2, 2024, subject to satisfaction of customary closing conditions. The gross proceeds to the Company from the exercise of the existing warrants and the issuance of new warrants are expected to be approximately $2.1 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes.

BBLG under $2

$2.43 still resistance offering price

BBLG..................................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

BBLG...$1.74...on the dip opportunity...🥳

georgie18

Member Level
Re: georgie18 post# 659336

Friday, September 27, 2024 10:15:04 AM

Post#
659570
of 660031
BBLG...$2.60...🥳

georgie18

Member Level
Re: georgie18 post# 136

Wednesday, September 25, 2024 3:57:43 PM

Post#
137
of 137
BBLG...$2.38s clearing off the $2.02 dip...🥳

georgie18

Member Level
Re: georgie18 post# 659229

Wednesday, September 25, 2024 12:01:49 PM

Post#
659269
of 659335
BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

BBLG...$2.60...🥳

georgie18

Member Level
Re: georgie18 post# 136

Wednesday, September 25, 2024 3:57:43 PM

Post#
137
of 137
BBLG...$2.38s clearing off the $2.02 dip...🥳

georgie18

Member Level
Re: georgie18 post# 659229

Wednesday, September 25, 2024 12:01:49 PM

Post#
659269
of 659335
BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

BBLG...$2.38s clearing off the $2.02 dip...🥳

georgie18

Member Level
Re: georgie18 post# 659229

Wednesday, September 25, 2024 12:01:49 PM

Post#
659269
of 659335
BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

BBLG...$2.17...adding the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 25, 2024 10:17:02 AM

Post#
135
of 135
BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

BBLG...$2.70...Upper Bollie Breakout here...Looking for $4...🥳

Pop

BBLG.....................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

BBLG..............................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

The fun isn’t over watch em come back for this again.

BBLG: Absolutely ZERO "news', Dude!!! (Don't you know that ZERO NEWS sends stocks SOARING for many, many, months now???)

What news accounts for this rise in BBLG’s share price? $1.72 real time.

$1.40 + 70%

BBLG under $2

BBLG............................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783

BBLG..............................https://stockcharts.com/h-sc/ui?s=BBLG&p=W&b=5&g=0&id=p86431144783